Table 1.
Selected demographic and clinical data and laboratory results of the study group prior to CRT implantation (Mann–Whitney U test with continuity correction).
| Variable | CHF (n = 76) | ||
|---|---|---|---|
| Median | Lower quartile | Upper quartile | |
| Age, years | 69 | 62.5 | 76 |
| Female gender, n (%) | 18 (23.68) | ||
| BMI, kg/m2 | 28.2 | 25.4 | 31.8 |
| Etiology of CHF, n (%) | |||
| CAD | 49 (64.1) | ||
| DCM | 23 (31.2) | ||
| Other | 4 (4.7) | ||
| LVEF (%) | 25 | 20 | 30 |
| NT-proBNP, pg/ml | 2916 | 1164 | 5918 |
| NYHA II, n (%) | 32 (42.11) | ||
| NYHA III, III/IV, or IV, n (%) | 44 (57.89) | ||
| Intraventricular conduction disorders, n (%) | |||
| LBBB | 59 (77.63) | ||
| 100% percentage of right ventricular pacing | 17 (22.37) | ||
| Chronic AF | 26 (34.38) | ||
| Paroxysmal AF | 18 (23.44) | ||
| QRS width, ms | 160 | 147 | 187 |
| CKD stadiums, n (%) | |||
| G1-G2 | 43 (56.58) | ||
| G3 | 30 (39.47) | ||
| G4 | 3 (3.95) | ||
| A1 | 48 (63.16) | ||
| A2 | 4 (5.26) | ||
| A3 | 24 (31.58) | ||
| Total cholesterol (mg/dl) | 171 | 144 | 200 |
| Cholesterol LDL (mg/dl) | 94 | 78 | 117 |
| Cholesterol HDL (mg/dl) | 42 | 35 | 49 |
| TG (mg/dl) | 131 | 94 | 168 |
| T2DM, n (%) | 31 (48.44) | ||
| HA, n (%) | 49 (76.56) | ||
| RAAS-Is used, n (%) | 76 (100) | ||
| Statin used, n (%) | 76 (100) | ||
Abbreviations: BMI, body mass index; CHF, chronic heart failure; CKD, chronic kidney disease stadium by KDIGO 2012 [1]; CAD, coronary artery disease, DCM, dilated cardiomyopathy; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-b-type natriuretic peptide levels were assessed; NYHA, New York Heart Association class; LBBB, left bundle branch block; RBBB, right bundle branch block; AF, atrial fibrillation; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides; T2DM, type 2 diabetes; HA, hypertension; RAAS-Is, renin-angiotensin-aldosterone system inhibiting drugs.